Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical
Artelo Biosciences (NASDAQ:ARTL) had its "hold" rating reaffirmed by analysts at Maxim Group.
Artelo Biosciences (NASDAQ:ARTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results